JD Health stock: AnalystLowTarget updates fair value for JD Health stock to HKD 49.90

Published on 10/23/2026 at 03:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 15.90 percent to CNY 40.90 billion in the first half of 2026. JD Health stock was last at HKD 37.98 on October 22, 2026.

Margin growth and valuation update

AnalystLowTarget moved fair value from HKD 49.44 to HKD 49.90 on October 3, 2026.
First-half 2026 revenue increased 15.90 percent to CNY 40.90 billion.
Non-IFRS operating profit grew 40.30 percent to CNY 3.50 billion in the first half of 2026.

JD Health, KYG5074A1004, Illustration mit AI erstellt.

JD Health's fair value was raised from HKD 49.44 to HKD 49.90 on October 3, 2026, in an update by AnalystLowTarget published through Simply Wall St. The update kept attention on margin progress while identifying regulation, research and development spending, and offline expansion as constraints.

Valuation meets faster profit growth

The revised fair value followed first-half results that combined double-digit sales growth with stronger operating leverage. GMT Eight reported that revenue reached CNY 40.90 billion in the first half of 2026, up 15.90 percent from the prior-year period. Non-IFRS operating profit increased 40.30 percent to CNY 3.50 billion, while the operating margin rose from 7.00 percent to 8.50 percent.

That spread between revenue and operating-profit growth is the central valuation issue. The business added CNY 6.50 billion of revenue year over year, while the reported operating-profit increase was CNY 1.00 billion, giving the margin expansion a measurable role in the investment case.

What does the margin mean?

For JD Health, the answer depends on whether higher-margin health services can offset the cost of expanding the platform. Simply Wall St cited a net margin of 7.90 percent versus 7.30 percent in the comparable period and highlighted regulation, drug pricing and competition as risks to future profitability.

Three dated steps for the stock

On August 13, 2026, JD Health reported first-half revenue of CNY 40.90 billion and non-IFRS operating profit of CNY 3.50 billion. On October 3, 2026, AnalystLowTarget raised fair value from HKD 49.44 to HKD 49.90. On October 17, 2026, Simply Wall St discussed the 7.90 percent net margin alongside the company's profitability trend.

Dates and market context

The first-half results covered the six months ended June 30, 2026, and were announced on August 13, 2026. The analyst valuation update was shared on October 3, 2026. On the Hong Kong Stock Exchange, JD Health was last at HKD 37.98 on October 22, 2026 at 4:08 p.m. HKT, with a 52-week range of HKD 31.84 to HKD 71.70.

Margin remains the key test

The improved 8.50 percent operating margin gives the valuation update a concrete operating reference, but the risk discussion keeps cost control central. The market's next assessment will depend on whether service expansion can preserve the first-half improvement.

The further course of trading is shown by the continuously updated real-time quote of JD Health stock.